ES2507520T3 - Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático - Google Patents

Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático Download PDF

Info

Publication number
ES2507520T3
ES2507520T3 ES09772115.3T ES09772115T ES2507520T3 ES 2507520 T3 ES2507520 T3 ES 2507520T3 ES 09772115 T ES09772115 T ES 09772115T ES 2507520 T3 ES2507520 T3 ES 2507520T3
Authority
ES
Spain
Prior art keywords
chondrocyte
adipocyte
isolation
potential
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09772115.3T
Other languages
English (en)
Inventor
Hans-Joerg Buehring
Sabrina Treml
Reiner Lammers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Application granted granted Critical
Publication of ES2507520T3 publication Critical patent/ES2507520T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso in vitro de un anticuerpo o fragmentos funcionales del anticuerpo, que se une al antígeno TNAP, en combinación con un anticuerpo o fragmentos funcionales del anticuerpo, que se une a CD56, para el aislamiento de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
    imagen2
ES09772115.3T 2008-06-30 2009-06-26 Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático Active ES2507520T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008032236A DE102008032236A1 (de) 2008-06-30 2008-06-30 Isolierung und/oder Identifizierung von Stammzellen mit adipozytärem, chondrozytärem und pankreatischem Differenzierungspotential
DE102008032236 2008-06-30
PCT/EP2009/004614 WO2010000415A1 (de) 2008-06-30 2009-06-26 Isolierung und/oder identifizierung von stammzellen mit adipozytärem, chondrozytärem und pankreatischem differenzierungspotential

Publications (1)

Publication Number Publication Date
ES2507520T3 true ES2507520T3 (es) 2014-10-15

Family

ID=41127757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09772115.3T Active ES2507520T3 (es) 2008-06-30 2009-06-26 Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático

Country Status (6)

Country Link
US (1) US9052316B2 (es)
EP (1) EP2313772B1 (es)
BR (1) BRPI0914127A2 (es)
DE (1) DE102008032236A1 (es)
ES (1) ES2507520T3 (es)
WO (1) WO2010000415A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
PT1888123E (pt) 2005-06-08 2013-03-13 Janssen Biotech Inc Uma terapêutica celular para a degeneração ocular
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
WO2009018453A1 (en) 2007-07-31 2009-02-05 Lifescan, Inc. Differentiation of human embryonic stem cells
CA2706560C (en) 2007-11-27 2017-02-28 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
DE102008032236A1 (de) 2008-06-30 2010-04-01 Eberhard-Karls-Universität Tübingen Isolierung und/oder Identifizierung von Stammzellen mit adipozytärem, chondrozytärem und pankreatischem Differenzierungspotential
PL2942392T3 (pl) 2008-06-30 2019-02-28 Janssen Biotech, Inc Różnicowanie pluripotencjalnych komórek macierzystych
MX349178B (es) 2008-10-31 2017-07-17 Centocor Ortho Biotech Inc Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
WO2010051223A1 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
KR101687344B1 (ko) 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
EP2366021B1 (en) 2008-11-20 2017-08-02 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
WO2011011300A2 (en) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
SG177416A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
EP2456858B1 (en) 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
RU2610176C2 (ru) 2009-12-23 2017-02-08 Янссен Байотек, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
MX339669B (es) 2009-12-23 2016-06-02 Janssen Biotech Inc Diferenciacion de celulas madres embrionarias humanas.
MX358451B (es) 2010-03-01 2018-08-20 Janssen Biotech Inc Métodos para purificar células derivadas de células madre pluripotenciales.
ES2728900T3 (es) 2010-05-12 2019-10-29 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas
CA2809305C (en) 2010-08-31 2019-06-11 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
WO2012030538A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
JP6218605B2 (ja) 2010-08-31 2017-10-25 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
DE102010045784B4 (de) * 2010-09-17 2022-01-20 OSRAM Opto Semiconductors Gesellschaft mit beschränkter Haftung Optoelektronischer Halbleiterchip
AU2012355698B2 (en) 2011-12-22 2018-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
AU2013230020B2 (en) 2012-03-07 2018-08-09 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
EP3450542B1 (en) 2012-06-08 2021-09-01 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
JP6373253B2 (ja) * 2012-07-17 2018-08-15 国立大学法人京都大学 新規心筋細胞マーカー
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
KR20150103203A (ko) 2012-12-31 2015-09-09 얀센 바이오테크 인코포레이티드 췌장 내분비 세포 내로의 분화를 위한 인간 만능 세포의 현탁 및 클러스터링
SG11201505112SA (en) 2012-12-31 2015-07-30 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
EP3019598A1 (en) * 2013-07-11 2016-05-18 INSERM - Institut National de la Santé et de la Recherche Médicale Method for obtaining a population of isolated brite adipocytes
DK3143127T3 (da) 2014-05-16 2021-09-13 Janssen Biotech Inc Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10242338A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung mesenchymaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung mesenchymaler Stammzellen
ES2654428T3 (es) * 2005-04-12 2018-02-13 Mesoblast, Inc. Aislamiento de células multipotenciales adultas por fosfatasa alcalina no específica de tejido
DE102006043625B4 (de) * 2006-09-12 2012-02-23 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zur Isolierung und/oder Identifizierung von mesenchymalen Stammzellen (MSC)
DE102008032236A1 (de) 2008-06-30 2010-04-01 Eberhard-Karls-Universität Tübingen Isolierung und/oder Identifizierung von Stammzellen mit adipozytärem, chondrozytärem und pankreatischem Differenzierungspotential

Also Published As

Publication number Publication date
EP2313772B1 (de) 2014-08-13
US9052316B2 (en) 2015-06-09
US20110117575A1 (en) 2011-05-19
DE102008032236A1 (de) 2010-04-01
BRPI0914127A2 (pt) 2019-09-24
WO2010000415A1 (de) 2010-01-07
EP2313772A1 (de) 2011-04-27

Similar Documents

Publication Publication Date Title
ES2507520T3 (es) Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
PA8850101A1 (es) Combinaciones antitumorales que contienen anticuerpos
BR112015015701A2 (pt) diferenciação de células-tronco embrionárias humanas em células pancreáticas endócrinas com o uso de reguladores hb9
CL2013003146A1 (es) Formulación estable que comprende anticuerpo anti alfa 4 beta 7 y al menos un aminoacido libre; metodo para preparar la formulación; uso para tratar enfermedad inflamatoria.
PA8850201A1 (es) Combinaciones antitumorales que contienen anticuerpos
CU20120095A7 (es) Antagonistas de pcsk9
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
SV2011003880A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
BR112012033005A2 (pt) artigo que tem uma superfície que pode ser escrita, método para a fabricação de uma superfície de escrita e método de uso de um artigo que tem uma superfície de escrita que pode ser reescrita
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
PA8850001A1 (es) Combinaciones antitumorales que contienen anticuerpos
ES2422429T3 (es) Diagnóstico del cáncer de próstata
CO6630181A2 (es) Composiciones y métodos para uso de anticuerpos terapéuticos de lrp6( proteina relacionada con lipoproteínas de baja densidad 6)
CR20110559A (es) Anticuerpos específicos para cadherina-17
ES2527454T3 (es) El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
ES2508165T3 (es) Lactoferrina y sustancia blanca